Health Trials

Stage IIIA Non-small Cell Lung Cancer

3

Review clinical trials related to Stage IIIA Non-small Cell Lung Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Pathological Response After Neoadjuvant Treatment on NSCLC

This is a non-interventional, observational, multicenter and retrospective study. Being limited to the collection of patient data already filled in the Tumor Thoracic Registry data base and the data from stage IIIA clinical trials case report forms.

Participants needed: 150
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Fundación GECPUpdated: Feb 6, 2026Locations: 17
Eligibility criteria

Patients with resectable stage IIIA disease (according to American Joint Committ... [+5]

Patients who received chemoradiotherapy neoadjuvant treatment [+2]

Read more
Status: Not yet recruiting

PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC

A Single-center, Single-arm Clinical Trial on the Safety and Efficacy of PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Stage IIIA Non-Small Cell Lung Cancer

Participants needed: 115
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shenzhen Celconta Life Science Co., Ltd.Updated: Jul 1, 2025
Eligibility criteria

Voluntarily participate in the clinical trial; fully understand and be informed... [+14]

NSCLC patients who have received neoadjuvant therapy; [+26]

Read more
Status: Not yet recruiting

Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy

This research trial studies biomarkers in predicting treatment response in samples from patients with early-stage non-small cell lung cancer previously treated with adjuvant chemotherapy. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

Participants needed: 950
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: National Cancer Institute (NCI)Updated: Sep 20, 2013Locations: 1
Eligibility criteria

International Adjuvant Lung Cancer Trail (IALT) [+5]

Read more